Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 7Plasmacytoma 2Paraproteinemias 2Leukemia, Plasma Cell 2Recurrence 1

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 6Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1Stem Cell Transplantation 1Ranitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Paraproteinemias × Steroids × Plasma cell × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡